Literature DB >> 15606382

Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity.

M H Tayebjee1, K T Tan, R J MacFadyen, G Y H Lip.   

Abstract

BACKGROUND: Peripheral arterial disease (PAD) is associated with adaptive changes in the vascular and muscle extracellular matrix (ECM) in response to reduced blood flow. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), are key modulators of ECM turnover. We hypothesized that patients with intermittent claudication (with low ankle-brachial blood pressure index, <0.8), and critical ischaemia would have raised circulating levels of MMP-9, TIMP-1 and TIMP-2 compared with healthy controls, reflecting an increase in proteolytic activity which may be related to ECM turnover in PAD.
METHODS: We studied 36 patients (23 males; 65 +/- 9 years) with intermittent claudication and 43 (25 males; 68 +/- 12) patients with critical ischaemia. All patients had angiographic evidence confirming significant PAD.
RESULTS: Circulating levels of MMP-9 and TIMP-1 were higher (both P < 0.0001) in the PAD patient groups compared with the controls. Patients with critical ischaemia had MMP-9 and TIMP-1 levels that were significantly higher than those with intermittent claudication. There were no differences in circulating TIMP-2 levels between patients and controls. There was a modest positive correlation between the white cell count (WCC) and MMP-9, both patients with intermittent claudication (Spearman, r = 0.398, P = 0.016) and critical ischaemia (r = 0.378, P = 0.014).
CONCLUSION: We demonstrate higher levels of circulating MMP-9 and TIMP-1 in patients with intermittent claudication and critical ischaemia. Circulating concentrations of both markers can be related to disease severity, being higher in critical ischaemia compared with levels in intermittent claudication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15606382     DOI: 10.1111/j.1365-2796.2004.01431.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  24 in total

1.  Critical limb ischemia.

Authors:  Paolo Gresele; Chiara Busti; Tiziana Fierro
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

2.  Relationship between matrix metalloproteinase-9 and common carotid artery intima media thickness.

Authors:  Maged Abdelnaseer; Nervana Elfayomi; Eman H Esmail; Manal M Kamal; Ahmed Hamdy; Rasha M Abdel Samie; Enji Elsawy
Journal:  Neurol Sci       Date:  2015-08-30       Impact factor: 3.307

3.  Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients.

Authors:  Ulf Diekmann; Ralf Zarbock; Doris Hendig; Christiane Szliska; Knut Kleesiek; Christian Götting
Journal:  J Mol Med (Berl)       Date:  2009-07-03       Impact factor: 4.599

4.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

5.  Pro-inflammatory effect of fibrinogen on vascular smooth muscle cells by regulating the expression of PPARα, PPARγ and MMP-9.

Authors:  Shuyue Wang; Juntian Liu; D I Wu; Xiaoming Pang; Jingjing Zhao; Xiaolu Zhang
Journal:  Biomed Rep       Date:  2015-05-04

Review 6.  Biomarkers of peripheral arterial disease.

Authors:  John P Cooke; Andrew M Wilson
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

7.  Despite normal arteriogenic and angiogenic responses, hind limb perfusion recovery and necrotic and fibroadipose tissue clearance are impaired in matrix metalloproteinase 9-deficient mice.

Authors:  Joshua K Meisner; Brian H Annex; Richard J Price
Journal:  J Vasc Surg       Date:  2014-02-28       Impact factor: 4.268

8.  Co-expressed immune and metabolic genes in visceral and subcutaneous adipose tissue from severely obese individuals are associated with plasma HDL and glucose levels: a microarray study.

Authors:  Marcel G M Wolfs; Sander S Rensen; Elinda J Bruin-Van Dijk; Froukje J Verdam; Jan-Willem Greve; Bahram Sanjabi; Marcel Bruinenberg; Cisca Wijmenga; Timon W van Haeften; Wim A Buurman; Lude Franke; Marten H Hofker
Journal:  BMC Med Genomics       Date:  2010-08-05       Impact factor: 3.063

Review 9.  Matrix metalloproteinases and peripheral arterial disease.

Authors:  Chiara Busti; Emanuela Falcinelli; Stefania Momi; Paolo Gresele
Journal:  Intern Emerg Med       Date:  2009-07-21       Impact factor: 3.397

10.  A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.